The Covid-19 vaccine data package submitted to the FDA comprises the chemistry

Novavax has submitted the final data package with the US Food and Drug Administration (FDA) to satisfy the requirements for seeking emergency use authorization (EUA) for its Covid-19 vaccine with Matrix-M adjuvant, NVX-CoV2373.

Engineered from the genetic sequence of the initial SARS-CoV-2 viral strain, the recombinant nanoparticle protein-based shot has purified protein antigen and cannot replicate or cause disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The submitted package comprises the chemistry, manufacturing and controls module and leverages the manufacturing collaboration of Novavax and the Serum Institute of India (SII).

Novavax plans to supplement the filing in the future with data from further production facilities across its supply chain worldwide.

With the latest development, the company intends to seek FDA EUA for the shot in a month as per the guidance of the regulatory agency.

Novavax president and CEO Stanley Erck said: “Novavax is committed to delivering our protein-based vaccine in the United States, where the Covid-19 pandemic continues to evolve with the emergence of new variants, ongoing need to ensure primary vaccination for the eligible population, and need for boosting.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In PREVENT-19 clinical trial that enrolled 25,452 subjects in the US and Mexico, the vaccine demonstrated an overall efficacy of 90.4%.

Furthermore, NVX-CoV2373 demonstrated an overall efficacy of 89.7% in a UK trial that enrolled 14,039 subjects.

In December last year, the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) to the Novavax’s vaccine to prevent Covid-19 in adult individuals of age 18 years and above.

With the EUA, the shot vaccine will be manufactured and supplied by SII as Covovax in the country.